IN THE CLAIMS:

Claim 1 (original): Stable, palatable syrup containing S(+)-ibuprofen, characterised in that it contains 0.01 to 2% (w/v) of S(+)-ibuprofen, preferably 1% of S(+)-ibuprofen, hydroxypropyl beta-cyclodextrin, at least one sweetener, water, and optionally essential oils, wherein the weight ratio of S(+)-ibuprofen to hydroxypropyl beta-cyclodextrin is 1:10 to 1: 18, preferably 1:10.8 to 1:12.

Claim 2 (original): The syrup according to claim 1, characterised in that the sweetener is selected from the group consisting of sucrose, sorbitol and glycerin, and preferably their combination.

Claim 3 (original): The syrup according to claim 1, characterised in that it contains one or more sweeteners selected from the group consisting of sucrose, sorbitol and glycerin, and preferably their combination, and one or more essential oils selected from the group consisting of lemon, orange, peppermint and lemongrass essential oils.

Claim 4 (original): A method of preparation of the syrup of claim 1, characterised in that crystalline S(+)-ibuprofen is dissolved at a temperature within the range from 15 to 50° C in a 29-43% (w/w) hydroxypropyl beta-cyclodextrin aqueous solution and the final S(+)-ibuprofen concentration is adjusted as desired by addition of aqueous solution of sweeteners and/or mixture of sweeteners and optionally of water.

Claim 5 (original): The method according to claim 4, characterised in that the

concentration of hydroxypropyl beta-cyclodextrin aqueous solution is 31 to 34% (w/w).

Claim 6 (original): The method according to claim 4, characterised in that the S(+)-ibuprofen is dissolved at temperature within the range from 40 to 45° C.

Claim 7 (original): A method of preparation of the syrup of claim 3, characterised in that crystalline S(+)-ibuprofen is dissolved at a temperature within the range from 15 to 50° C in a 29-43% (w/w) hydroxypropyl beta-cyclodextrin aqueous solution, the resulting solution is combined with a solution of an essential oil in a suitable sweetener or mixture of sweeteners, preferably in a mixture of glycerin and 70% sorbitol aqueous solution, and the final S(+)-ibuprofen concentration is adjusted as desired by addition of an aqueous solution of sweetener and/or mixture of sweeteners and optionally of water.

Claim 8 (original): The method according to claim 7, characterised in that the concentration of hydroxypropyl beta-cyclodextrin aqueous solution is 31 to 34% (w/w).

Claim 9 (original): The method according to claim 7, characterised in that the S(+)-ibuprofen is dissolved at temperature within the range from 15 to 50° C, preferably within the range from 40 to 45° C.

Claim 10 (original): The method according to claim 7, characterised in that the essential oils are added in the form of a clear solution.